Skip to main content
Erschienen in: Infection 1/2011

01.02.2011 | Brief Report

Impact of an antibiotic restriction program on antibiotic utilization in the treatment of community-acquired pneumonia in a Veterans Affairs Medical Center

verfasst von: M. D. Mansouri, R. M. Cadle, S. O. Agbahiwe, D. M. Musher

Erschienen in: Infection | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The impact of an antibiotic restriction program (ARP) on the patterns of antibiotic use in the treatment of community-acquired pneumonia (CAP) was examined. We also evaluated the association between the ARP and the length of hospital stay in regard to CAP treatment and cost savings associated with the implementation of the ARP.

Methods

A retrospective cohort study of patients admitted with CAP was conducted during two 6-month periods, one prior to the ARP and one after the ARP. The health system’s computerized patient record system (CPRS) was used to obtain demographics, length of hospital stays, readmission rates, blood culture results, co-morbidities, antibiotic use, and durations of therapy. A total of 130 patients met the inclusion criteria for the final analyses. Average drug costs, employee salaries, and the cost of laboratory procedures were used to assess cost savings associated with the ARP.

Results

From a total of 132 antibiotics that were ordered to treat CAP in the pre-ARP period, 28 were restricted (21.2%). However, the number of restricted antibiotics ordered was significantly reduced to 12 out of 114 (10.2%) antibiotics ordered in the post-ARP period (P = 0.024). In post-ARP implementation, the mean length of hospital stay was also significantly reduced from 7.6 to 5.8 days (P = 0.017), and although not statistically significant, the 30-day readmission rates declined from 16.9 to 6.2% (P = 0.097). The ARP was also associated with a saving of $943 per patient treated for CAP.

Conclusions

In addition to a decrease in the antibiotic utilization and the mean length of hospital stay, the ARP may have yielded cost savings and reduced the readmission rates for those patients admitted and treated for CAP.
Literatur
1.
Zurück zum Zitat John JF Jr, Fishman NO. Programmatic role of the infectious diseases physician in controlling antimicrobial costs in the hospital. Clin Infect Dis. 1997;24:471–85.PubMed John JF Jr, Fishman NO. Programmatic role of the infectious diseases physician in controlling antimicrobial costs in the hospital. Clin Infect Dis. 1997;24:471–85.PubMed
2.
Zurück zum Zitat Pakyz AL, MacDougall C, Oinonen M, Polk RE. Trends in antibacterial use in US academic health centers: 2002 to 2006. Arch Intern Med. 2008;168:2254–60.PubMedCrossRef Pakyz AL, MacDougall C, Oinonen M, Polk RE. Trends in antibacterial use in US academic health centers: 2002 to 2006. Arch Intern Med. 2008;168:2254–60.PubMedCrossRef
3.
Zurück zum Zitat Tobia CC, Aspinall SL, Good CB, Fine MJ, Hanlon JT. Appropriateness of antibiotic prescribing in veterans with community-acquired pneumonia, sinusitis, or acute exacerbations of chronic bronchitis: a cross-sectional study. Clin Ther. 2008;30:1135–44.PubMedCrossRef Tobia CC, Aspinall SL, Good CB, Fine MJ, Hanlon JT. Appropriateness of antibiotic prescribing in veterans with community-acquired pneumonia, sinusitis, or acute exacerbations of chronic bronchitis: a cross-sectional study. Clin Ther. 2008;30:1135–44.PubMedCrossRef
4.
Zurück zum Zitat Tacconelli E. Antimicrobial use: risk driver of multidrug resistant microorganisms in healthcare settings. Curr Opin Infect Dis. 2009;22:352–8.PubMedCrossRef Tacconelli E. Antimicrobial use: risk driver of multidrug resistant microorganisms in healthcare settings. Curr Opin Infect Dis. 2009;22:352–8.PubMedCrossRef
6.
Zurück zum Zitat Dellit TH, Owens RC, McGowan JE Jr, Gerding DN, Weinstein RA, Burke JP, Huskins WC, Paterson DL, Fishman NO, Carpenter CF, Brennan PJ, Billeter M, Hooton TM. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44:159–77.PubMedCrossRef Dellit TH, Owens RC, McGowan JE Jr, Gerding DN, Weinstein RA, Burke JP, Huskins WC, Paterson DL, Fishman NO, Carpenter CF, Brennan PJ, Billeter M, Hooton TM. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44:159–77.PubMedCrossRef
7.
Zurück zum Zitat Apisarnthanarak A, Danchaivijitr S, Khawcharoenporn T, Limsrivilai J, Warachan B, Bailey TC, Fraser VJ; Thammasart University Antibiotic Management Team. Effectiveness of education and an antibiotic-control program in a tertiary care hospital in Thailand. Clin Infect Dis. 2006;42:768–75.PubMedCrossRef Apisarnthanarak A, Danchaivijitr S, Khawcharoenporn T, Limsrivilai J, Warachan B, Bailey TC, Fraser VJ; Thammasart University Antibiotic Management Team. Effectiveness of education and an antibiotic-control program in a tertiary care hospital in Thailand. Clin Infect Dis. 2006;42:768–75.PubMedCrossRef
8.
Zurück zum Zitat Gould IM, Jappy B. Trends in hospital antibiotic prescribing after introduction of an antibiotic policy. J Antimicrob Chemother. 1996;38:895–904.PubMedCrossRef Gould IM, Jappy B. Trends in hospital antibiotic prescribing after introduction of an antibiotic policy. J Antimicrob Chemother. 1996;38:895–904.PubMedCrossRef
9.
Zurück zum Zitat Klapp DL, Ramphal R. Antibiotic restriction in hospitals associated with medical schools. Am J Hosp Pharm. 1983;40:1957–60.PubMed Klapp DL, Ramphal R. Antibiotic restriction in hospitals associated with medical schools. Am J Hosp Pharm. 1983;40:1957–60.PubMed
10.
Zurück zum Zitat Nuila F, Cadle RM, Logan N, Musher DM. Antibiotic stewardship and Clostridium difficile-associated disease. Infect Control Hosp Epidemiol. 2008;29:1096–7.PubMedCrossRef Nuila F, Cadle RM, Logan N, Musher DM. Antibiotic stewardship and Clostridium difficile-associated disease. Infect Control Hosp Epidemiol. 2008;29:1096–7.PubMedCrossRef
11.
Zurück zum Zitat Muto CA, Pokrywka M, Shutt K, Mendelsohn AB, Nouri K, Posey K, Roberts T, Croyle K, Krystofiak S, Patel-Brown S, Pasculle AW, Paterson DL, Saul M, Harrison LH. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol. 2005;26:273–80.PubMedCrossRef Muto CA, Pokrywka M, Shutt K, Mendelsohn AB, Nouri K, Posey K, Roberts T, Croyle K, Krystofiak S, Patel-Brown S, Pasculle AW, Paterson DL, Saul M, Harrison LH. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol. 2005;26:273–80.PubMedCrossRef
12.
Zurück zum Zitat Price J, Cheek E, Lippett S, Cubbon M, Gerding DN, Sambol SP, Citron DM, Llewelyn M. Impact of an intervention to control Clostridium difficile infection on hospital- and community-onset disease; an interrupted time series analysis. Clin Microbiol Infect. 2010;16:1297–302.PubMedCrossRef Price J, Cheek E, Lippett S, Cubbon M, Gerding DN, Sambol SP, Citron DM, Llewelyn M. Impact of an intervention to control Clostridium difficile infection on hospital- and community-onset disease; an interrupted time series analysis. Clin Microbiol Infect. 2010;16:1297–302.PubMedCrossRef
13.
Zurück zum Zitat Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, Torres A, Whitney CG; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44:S27–72.PubMedCrossRef Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, Torres A, Whitney CG; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44:S27–72.PubMedCrossRef
14.
Zurück zum Zitat Polgreen PM, Chen YY, Cavanaugh JE, Ward M, Coffman S, Hornick DB, Diekema DJ, Herwaldt LA. An outbreak of severe Clostridium difficile-associated disease possibly related to inappropriate antimicrobial therapy for community-acquired pneumonia. Infect Control Hosp Epidemiol. 2007;28:212–4.PubMedCrossRef Polgreen PM, Chen YY, Cavanaugh JE, Ward M, Coffman S, Hornick DB, Diekema DJ, Herwaldt LA. An outbreak of severe Clostridium difficile-associated disease possibly related to inappropriate antimicrobial therapy for community-acquired pneumonia. Infect Control Hosp Epidemiol. 2007;28:212–4.PubMedCrossRef
15.
Zurück zum Zitat Johnson D, Carriere KC, Jin Y, Marrie T. Appropriate antibiotic utilization in seniors prior to hospitalization for community-acquired pneumonia is associated with decreased in-hospital mortality. J Clin Pharm Ther. 2004;29:231–9.PubMedCrossRef Johnson D, Carriere KC, Jin Y, Marrie T. Appropriate antibiotic utilization in seniors prior to hospitalization for community-acquired pneumonia is associated with decreased in-hospital mortality. J Clin Pharm Ther. 2004;29:231–9.PubMedCrossRef
16.
Zurück zum Zitat Halm EA, Teirstein AS. Clinical practice. Management of community-acquired pneumonia. N Engl J Med. 2002;347:2039–45.PubMedCrossRef Halm EA, Teirstein AS. Clinical practice. Management of community-acquired pneumonia. N Engl J Med. 2002;347:2039–45.PubMedCrossRef
17.
18.
Zurück zum Zitat International Classification of Diseases, 9th Revision. 6th ed. Clinical Modification (ICD-9 codes). Practice Management Information Corporation. 2005. International Classification of Diseases, 9th Revision. 6th ed. Clinical Modification (ICD-9 codes). Practice Management Information Corporation. 2005.
19.
Zurück zum Zitat Ebnöther C, Tanner B, Schmid F, La Rocca V, Heinzer I, Bregenzer T. Impact of an infection control program on the prevalence of nosocomial infections at a tertiary care center in Switzerland. Infect Control Hosp Epidemiol. 2008;29:38–43.PubMedCrossRef Ebnöther C, Tanner B, Schmid F, La Rocca V, Heinzer I, Bregenzer T. Impact of an infection control program on the prevalence of nosocomial infections at a tertiary care center in Switzerland. Infect Control Hosp Epidemiol. 2008;29:38–43.PubMedCrossRef
20.
Zurück zum Zitat Bhattacharyya BK. Antibiotic resistance—a close look. Hindustan Antibiot Bull. 1999;41:25–31.PubMed Bhattacharyya BK. Antibiotic resistance—a close look. Hindustan Antibiot Bull. 1999;41:25–31.PubMed
21.
Zurück zum Zitat Hall CS, Ost DE. Effectiveness of programs to decrease antimicrobial resistance in the intensive care unit. Semin Respir Infect. 2003;18:112–21.PubMed Hall CS, Ost DE. Effectiveness of programs to decrease antimicrobial resistance in the intensive care unit. Semin Respir Infect. 2003;18:112–21.PubMed
22.
Zurück zum Zitat Paterson DL. Restrictive antibiotic policies are appropriate in intensive care units. Crit Care Med. 2003;31:S25–8.PubMedCrossRef Paterson DL. Restrictive antibiotic policies are appropriate in intensive care units. Crit Care Med. 2003;31:S25–8.PubMedCrossRef
23.
Zurück zum Zitat Shlaes DM, Gerding DN, John JF Jr, Craig WA, Bornstein DL, Duncan RA, Eckman MR, Farrer WE, Greene WH, Lorian V, Levy S, McGowan JE Jr, Paul SM, Ruskin J, Tenover FC, Watanakunakorn C. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Infect Control Hosp Epidemiol. 1997;18:275–91.PubMedCrossRef Shlaes DM, Gerding DN, John JF Jr, Craig WA, Bornstein DL, Duncan RA, Eckman MR, Farrer WE, Greene WH, Lorian V, Levy S, McGowan JE Jr, Paul SM, Ruskin J, Tenover FC, Watanakunakorn C. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Infect Control Hosp Epidemiol. 1997;18:275–91.PubMedCrossRef
24.
Zurück zum Zitat Gould IM. A review of the role of antibiotic policies in the control of antibiotic resistance. J Antimicrob Chemother. 1999;43:459–65.PubMedCrossRef Gould IM. A review of the role of antibiotic policies in the control of antibiotic resistance. J Antimicrob Chemother. 1999;43:459–65.PubMedCrossRef
25.
Zurück zum Zitat White AC Jr, Atmar RL, Wilson J, Cate TR, Stager CE, Greenberg SB. Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis. 1997;25:230–9.PubMedCrossRef White AC Jr, Atmar RL, Wilson J, Cate TR, Stager CE, Greenberg SB. Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis. 1997;25:230–9.PubMedCrossRef
26.
Zurück zum Zitat Bassetti M, Di Biagio A, Rebesco B, Amalfitano ME, Topal J, Bassetti D. The effect of formulary restriction in the use of antibiotics in an Italian hospital. Eur J Clin Pharmacol. 2001;57:529–34.PubMedCrossRef Bassetti M, Di Biagio A, Rebesco B, Amalfitano ME, Topal J, Bassetti D. The effect of formulary restriction in the use of antibiotics in an Italian hospital. Eur J Clin Pharmacol. 2001;57:529–34.PubMedCrossRef
27.
Zurück zum Zitat Tang H, Huang T, Jing J, Shen H, Cui W. Effect of procalcitonin-guided treatment in patients with infections: a systematic review and meta-analysis. Infection. 2009;37:497–507.PubMedCrossRef Tang H, Huang T, Jing J, Shen H, Cui W. Effect of procalcitonin-guided treatment in patients with infections: a systematic review and meta-analysis. Infection. 2009;37:497–507.PubMedCrossRef
Metadaten
Titel
Impact of an antibiotic restriction program on antibiotic utilization in the treatment of community-acquired pneumonia in a Veterans Affairs Medical Center
verfasst von
M. D. Mansouri
R. M. Cadle
S. O. Agbahiwe
D. M. Musher
Publikationsdatum
01.02.2011
Verlag
Springer-Verlag
Erschienen in
Infection / Ausgabe 1/2011
Print ISSN: 0300-8126
Elektronische ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-010-0078-0

Weitere Artikel der Ausgabe 1/2011

Infection 1/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.